ASP I (Ancrod Stroke Program) Study of acute Viprinex for emergency stroke: a randomized, double-blind, placebo-controlled study of ancrod (Viprinex) in subjects beginning treatment within 6 hours of the onset of acute, ischemic stroke
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Ancrod (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Therapeutic Use
- Acronyms ASP-I
- 29 Dec 2009 Actual number of patients changed from 353 to 227 as reported by ClinicalTrials.gov record.
- 14 Jan 2009 Actual patient number reported as 353 by ClinicalTrials.gov.
- 14 Jan 2009 Actual end date reported as December 2008 by ClinicalTrials.gov.